• en
  • it
  • de
  • Farmabios expands its portfolio with Cannabidiol API

    Global API supplier Farmabios announced today the addition of an ultra-pure synthetic Cannabidiol (CBD) drug substance to its portfolio. With an EU Drug Master File and cGMP manufacturing capacities, Farmabios is now positioned to fulfill a secure and scalable supply of CBD, from clinical needs to full-scale commercial operations. “As a long-standing supplier of specialized APIs, we are very pleased to add this GMP grade Cannabidiol to our growing portfolio. CBD has the potential to open new and larger markets for the industry. We’re excited to expand our ability to work with our existing customers as well as new ones, as we respond to the increasing market demand for CBD-based APIs,” said Farmabios General Manager Mario Di Giacomo.

    As part of the PharmaZell Group, Farmabios is the leading global manufacturer of non-sterile and sterile steroids and offers custom development and manufacturing services of a focused portfolio of High Potent Substances (HPS) and anticancer drugs. With decades of steroid chemistry expertise and ongoing research and development activities, Farmabios provides a flexible approach that meets the specific requirements of each customer.

    About The PharmaZell Group:

    The PharmaZell Group consists of three companies – PharmaZell, Farmabios and Pharmachol who supply the pharmaceutical industry with Active Pharmaceutical Ingredients. The Group operates production facilities in Germany, Italy and India and enables its companies to secure the industry’s supply chain as trusted drug substance suppliers. Over 900 people work for the PharmaZell Group worldwide.

    Key Group Facts:

    • More than €170 million revenue in 2018
    • Compound annual growth rate of 8.5% over the last decade
    • A strong and competitive industry leader, ranked among the top three producers for most Pharmazell products
    • State-of-the-art proprietary, large-scale electrochemical processes
    • Proprietary enzymatic route of synthesis for cholic acid derivatives

    Please contact Mr. Michel Blanc, michel.blanc@pharmazell.com for further information.

    More News and Fairs

    We are very glad to announce that AIFA renewed the complete GMP certificate for Farmabios on July 7th 2020 SpA facility

    We are very glad to announce that AIFA renewed the complete GMP certificate for Farmabios on July 7th 2020 SpA facility

    Farmabios expands its Manufacturing Footprint in Gropello Cairoli (Italy)

    The construction of a brand new large steroid building and a new warehouse on the Farmabios premises in Gropello Cairoli (Italy) is moving forward nearly in plan. After construction work

    Acquisition of PharmaZell Group by Bridgepoint completed. PharmaChol fully owned by the PharmaZell Group.

    Bridgepoint, an international asset management firm with over €20 billion of assets, announced the acquisition of the PharmaZell Group in February 2020. After obtaining all necessary authorizations, we are very

    CURRENT COVID-19 OUTBREAK: SUPPORTIVE HELP

    Farmabios is pleased to announce that it has just finalized the production and distribution of sanitizing gels to Covid-19 task forces and structures which are serving the neighboring area, as

    UPDATE 4: IMPACT OF THE CURRENT COVID-19 OUTBREAK ON INDIAN PRODUCTION SITES

    PharmaZell Group is very conscious of our important role and duty in delivering APIs to our customers and being an active part in maintaining the health system running. Up to

    FarmaBios activities are regularly proceeding…

    During this critical and challenging period, Farmabios SpA states that our activities are regularly proceeding. We are conscious of the role and duty in delivering APIs, and our active part

    Breaking News: PharmaZell Group acquired by Bridgepoint

    The PharmaZell Group management is very pleased to inform that the Group was acquired by Bridgepoint from DPE Deutsche Private Equity and Maxburg Capital Partners for an undisclosed sum. Bridgepoint

    Farmabios Breaks Ground to Expand its Manufacturing Footprint in Gropello Cairoli (Italy)

    As part of an ongoing investment program to enhance PharmaZell Group’s production output, we have initiated the construction of a brand new large steroid building and a new warehouse on

    Renewed GMP Certificate for our Manufacturing Facility Farmabios in Gropello Cairoli (Italy)

    We are very glad to announce that the competent Italian authority (AIFA) has issued a renewed GMP certificate for our Farmabios SpA production facility [http://eudragmdp.ema.europa.eu/inspections/gmpc/generateGMPCPDF.do].

    Farmabios expands its portfolio with Cannabidiol API

    Global API supplier Farmabios announced today the addition of an ultra-pure synthetic Cannabidiol (CBD) drug substance to its portfolio. With an EU Drug Master File and cGMP manufacturing capacities, Farmabios